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Introduction
A 73-year-old female patient with osteoporosis, who 
had been taking alendronate for over 15 years, 
sustained bilateral, atypical femoral fractures two 
years apart. There was evidence of a stress fracture 
preceding the current fracture, as seen in the X-rays 
performed two years prior. Subsequently, she was 
found to have primary hyperparathyroidism. 
Case report
A 73 year-old female patient was admitted to the 
orthogeriatrics unit at Helen Joseph Hospital in 2012 
with a fracture of her right femur, following a fall 
from standing height. She was known to have severe 
osteoporosis, having sustained multiple previous fragility 
fractures involving her right distal radius, left olecranon 
and left proximal humerus. She had been admitted in 
2010 with a low-trauma femur fracture on the opposite 
(left) side, and recalled that she had complained of 
right thigh pain at the time. Risk factors for osteoporosis 
included smoking, being of the female sex and of 
an older age. She had been taking oral alendronate 
continuously for the past 15 years, as well as vitamin D 
supplementation. At the time of her 2012 admission, her 
kidney function and thyroid-stimulating hormone levels 
were within the normal ranges. Her serum-corrected 
calcium was 2.39 mmol/l (2.05-2.56 mmol/l), her serum 
magnesium level 0.93 mmol/l (0.65-1.1 mmol/l), and 
serum phosphate level 1.03 mmol/l (0.80-1.40 mmol/l). 
Figures 1 and 2 show that the initial left femur fracture 
was transverse, non-comminuted and subtrochanteric, 
with an apparent thickening of the lateral cortex at the 
site of the fracture representing a periosteal reaction 
(“flaring”), and a medial spike that is characteristic of 
atypical femoral fractures.1,2 Figures 1 and 3 show a 
lateral cortical ridge, indicating a stress fracture of the 
right femur, present at the time of the initial fracture in 
2010. Subsequently, in 2012, she developed an atypical 
femoral fracture of her right femur at that site as well 
Figure 4). 
The patient underwent successful surgical fixation 
of the fracture and recovered uneventfully. Oral 
bisphosphonate therapy was stopped and calcium 
and vitamin D supplementation continued. She was 
seen at a follow-up appointment one month after 
discharge, and was then found to have high corrected 
calcium levels of 2.77 mmol/l (2.05-2.56 mmol/l), with 
an associated high parathyroid hormone level of 
8.7 pmol/l (1.2-8.5 pmol/l). Total 25-hydroxyvitamin 
D level at the time was 31.21 nmol/l. A parathyroid 
sestamibi scan localised a left inferior parathyroid 
adenoma. At the time of writing, she was awaiting 
surgical assessment for possible parathyroidectomy. 
The patient provided written informed consent to 
anonymous publication of her case details.
Parathyroid hormone can increase both the formation 
and resorption of bone, depending on whether or 
not it is administered intermittently or continuously. 
Intermittent administration causes a net increase in 
trabecular bone mass, with little net effect on cortical 
bone mass. In primary hyperparathyroidism, the 
continuously elevated parathyroid hormone has little 
impact on the trabecular bone and a decrease in the 
cortical bone.3
Atypical femoral fractures (AFFs) occur rarely. It is 
important to differentiate AFFs from other fractures of 
the femoral diaphysis, such as osteoporotic, malignant, 
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Figure 1: An antero-posterior pelvis X-ray performed in May 
2010, showing the initial left atypical femoral fracture with 
subtrochanteric stress fracture (visible on the right)
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pathological, peri-prosthetic and major trauma-
related fractures. The American Society for Bone 
and Mineral Research (ABMR) consensus criteria for 
the radiological features of the case definition have 
recently been amended.2 These fractures occur with 
minimal force, but are often preceded by a painful 
prodrome. Sometimes X-ray changes consistent 
with a stress fracture may be visible before frank 
displacement occurs. They are characterised by an 
unusual X-ray appearance in the circumstances of 
a low-trauma injury (as described in the case report 
above), or even by spontaneous occurrence, as well 
as by a high incidence of bilaterality and delayed 
healing. Because of frequent bilateral involvement, the 
contralateral femur should undergo imaging. If a stress 
fracture is seen, then prophylactic surgical fixation is 
recommended, although conservative management 
can be considered in certain situations.2 
The pathophysiology of AFFs is thought to be owing 
to over-suppression of bone turnover, with an 
accumulation of microcracks due to the adynamic 
bone that has lost the ability to repair. These microcracks 
propagate and weaken the bony area, leading to 
eventual complete fracture. The subtrochanteric 
region of the femur, usually one of the strongest parts 
of the femur, becomes vulnerable as it is the site of 
maximal bending force.1
An increased risk of AFFs is associated with specific 
diseases and drug exposure, as well as particular lower 
limb geometry. Once the diagnosis has been made, 
such associations should be sought. Importantly, AFFs 
have also occurred in patients with no apparent risk 
factors.2
Atypical femoral fractures occur more often in patients 
on bisphosphonate therapy. A longer duration of 
treatment increases the risk. A cohort study carried 
out in the USA reported an incidence of 1.78/100 000/
year in patients exposed to bisphosphonates for 0.1-1.9 
years, which increased to 113.1/100 000/year in patients 
exposed for 8-8.9 years.4 Stopping bisphosphonate 
therapy reduces the subsequent risk.5 The relative 
risk in patients on long-term bisphosphonates varies 
between studies, but is high, ranging from 2.11-128, and 
increases with increasing duration of therapy. However, 
the absolute risk remains extremely low at 3.2-50/100 
000 patient-years. Other associations that have been 
reported are glucocorticoid therapy, denosumab, 
proton-pump inhibitors, low vitamin D levels, rheum-
atoid arthritis, being of the Asian race and type 2 
diabetes mellitus.2 To our knowledge, atypical femur 
fractures fulfilling ABMR consensus criteria such as these 
have not been reported in association with primary 
hyperparathyroidism, although this may be because 
of under-reporting. The case definition for these 
fractures was only formalised in 2009, and prior studies 
Figure 3: A closer view of the lateral cortical ridge, indicating a 
stress fracture of the right femur
Figure 2: A closer view of the left atypical femoral fracture. 
It is transverse, non-comminuted, subtrochanteric, with an 
apparent thickening of the lateral cortex at the site of fracture 
representing a periosteal reaction (“flaring”), and a medial spike 
that is characteristic of atypical femoral fractures
Figure 4: An antero-posterior pelvis X-ray taken in September 
2012, showing the subsequent atypical fracture occurring at the 
site of the stress fracture on the right femur
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may have reported fractures as “proximal femoral”, 
without differentiating this important subcategory. 
Epidemiological research, using International Classif-
ication of Diseases codes, has shown a high proportion 
of incorrectly coded fractures.2 
We postulate that primary hyperparathyroidism 
predisposed our patient to develop fractures. We also 
postulate that long-term bisphosphonate therapy 
contributed to the development of atypical femoral 
fractures since the radiological features of thickening 
of the lateral cortex were not consistent with bone 
changes because of the hyperparathyroidism alone. 
Our case demonstrates that patients with hip fractures 
require follow-up to ascertain the cause and facilitate 
management of their bone disease.  
Bisphosphonates are extremely safe, with proven 
efficacy over four years at reducing the risk of vertebral 
and non-vertebral fractures in women with osteoporosis. 
The risk of atypical femoral fractures is low, compared 
to the risk of hip fractures in untreated osteoporosis. 
For example, 300 hip fractures are expected in 
10 000 high-risk patients/year. Bisphosphonate therapy 
reduces the number of hip fractures by preventing 
108 hip fractures over five years of treatment, with only 
3-6 subtrochanteric fractures gained.6 Therefore, the 
benefit of bisphosphonate therapy greatly outweighs 
the risk in patients with osteoporosis. Bisphosphonates 
have lasting effects on bone mineral density and 
bone markers after treatment has ceased.7 Given the 
paucity of data, in particular on nonvertebral fracture 
reduction beyond four years, as well as the recognition 
of rare, but important, adverse events associated with 
prolonged therapy, concern has been generated 
regarding long-term uninterrupted use of these agents. 
The current National Osteoporosis Foundation of South 
Africa guideline recommends that after five years of 
bisphosphonate treatment, a drug holiday should be 
considered. Switching to alternative drugs, such as 
strontium ranelate or teriparatide, is recommended for 
high-risk patients.8
References
1. Masoodi NA. Bisphosphonates and atypical femur fractures. British Journal of Medical 
Practitioners. 2010;3(1):311-312.
2. Shane E, Ebeling PR, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal 
femoral fractures: second report of a task force of the American society for bone and 
mineral research. J Bone Min Res. 2013 [Epub ahead of print]. PubMed [homepage on 
the Internet]. c2013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23712442
3. Kronenberg HM. Williams textbook of endocrinology. 11th ed. In: Melmed S, Polonsky 
KS, Larsen PR, editors. Philadelphia: Saunders, 2008; p. 1210-1211. 
4. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal 
fractures of the femur. J Bone Min Res. 2012;27(12):2544-25450. 
5. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures 
of the femoral shaft. New Eng J Med. 2011;364(18):1728-37.
6. Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term 
treatment with bisphosphonates: a European Society on Clinical and Economic 
Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation 
Working Group Report. Osteoporos Int. 2011;22(2):373-390.
7. Black DM, Schwartz A V, Ensrud KE, et al. Effects of continuing or stopping alendronate 
after 5 years of treatment. JAMA. 2006;296(24):2927-2938.
8. Hough S, Ascott-Evans B, Brown S, et al. NOFSA guideline for the diagnosis and 
management of osteoporosis. JEMDSA. 2010;15(3):107-108.
 
C
M
Y
CM
MY
CY
CMY
K
